Zacks: Analysts Anticipate ZIOPHARM Oncology Inc. (ZIOP) to Announce -$0.12 EPS
Equities analysts expect ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to announce earnings per share (EPS) of ($0.12) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for ZIOPHARM Oncology’s earnings, with the highest EPS estimate coming in at ($0.09) and the lowest estimate coming in at ($0.14). ZIOPHARM Oncology posted earnings per share of ($0.09) in the same quarter last year, which suggests a negative year over year growth rate of 33.3%. The firm is expected to issue its next earnings report on Tuesday, May 9th.
According to Zacks, analysts expect that ZIOPHARM Oncology will report full-year earnings of ($0.56) per share for the current fiscal year, with EPS estimates ranging from ($0.78) to ($0.43). For the next year, analysts expect that the business will report earnings of ($0.67) per share, with EPS estimates ranging from ($0.96) to ($0.45). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for ZIOPHARM Oncology.
Several equities analysts have recently commented on the company. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of ZIOPHARM Oncology in a research note on Thursday, January 12th. Griffin Securities reaffirmed a “buy” rating and issued a $23.00 price target (up previously from $21.00) on shares of ZIOPHARM Oncology in a research note on Friday, February 10th. Finally, Zacks Investment Research lowered ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, April 6th. One analyst has rated the stock with a sell rating, four have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $10.15.
ZIOPHARM Oncology (NASDAQ:ZIOP) traded up 0.28% on Monday, hitting $7.10. 1,216,951 shares of the company were exchanged. The stock’s market capitalization is $927.94 million. The stock’s 50-day moving average price is $6.47 and its 200-day moving average price is $6.16. ZIOPHARM Oncology has a 52-week low of $4.45 and a 52-week high of $8.86.
ILLEGAL ACTIVITY WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at http://www.watchlistnews.com/zacks-analysts-anticipate-ziopharm-oncology-inc-ziop-to-announce-0-12-eps/1205958.html.
Several institutional investors have recently made changes to their positions in ZIOP. Wells Fargo & Company MN raised its position in shares of ZIOPHARM Oncology by 1.4% in the third quarter. Wells Fargo & Company MN now owns 156,929 shares of the biotechnology company’s stock valued at $883,000 after buying an additional 2,159 shares during the period. National Planning Corp raised its position in shares of ZIOPHARM Oncology by 8.7% in the fourth quarter. National Planning Corp now owns 32,093 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 2,569 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of ZIOPHARM Oncology by 0.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 580,992 shares of the biotechnology company’s stock valued at $3,271,000 after buying an additional 2,930 shares during the period. Teachers Advisors LLC raised its position in shares of ZIOPHARM Oncology by 1.9% in the fourth quarter. Teachers Advisors LLC now owns 198,508 shares of the biotechnology company’s stock valued at $1,062,000 after buying an additional 3,699 shares during the period. Finally, Ray Gerald L & Associates Ltd. raised its position in shares of ZIOPHARM Oncology by 16.8% in the third quarter. Ray Gerald L & Associates Ltd. now owns 29,209 shares of the biotechnology company’s stock valued at $164,000 after buying an additional 4,200 shares during the period. 41.26% of the stock is currently owned by institutional investors and hedge funds.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.